Milestone Pharmaceuticals (MIST) Other Non-Current Liabilities (2020 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Other Non-Current Liabilities came in at $55.6 million in Q1 2026, up 4.85% YoY from $53.1 million in Q1 2025, and up 66946.99% on a QoQ basis from $83000.0 in Q4 2025.
Milestone Pharmaceuticals (MIST) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 7 years of Other Non-Current Liabilities data on file, last reported at $55.6 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 4.85% year-over-year to $55.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.6 million (up 4.85% YoY) and the FY2025 annual result came in at $83000.0, down 99.84% from the prior year.
- Other Non-Current Liabilities climbed to $55.6 million in Q1 2026, from $83000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $55.6 million in Q3 2025 to a low of $83000.0 in Q4 2025.
- A 5-year average of $48.0 million and a median of $52.9 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 41.07% — and 2025, when it sank 99.84%.
- Tracing MIST's Other Non-Current Liabilities over 5 years: stood at $34.4 million in 2022, then surged by 41.07% to $48.5 million in 2023, then grew by 9.53% to $53.1 million in 2024, then slumped by 99.84% to $83000.0 in 2025, then soared by 66946.99% to $55.6 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $55.6 million (Q1 2026), $83000.0 (Q4 2025), and $55.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.65 Mn |
| Mar 31, 2026 | 55.65 Mn |
| Dec 31, 2025 | 83,000.00 |
| Sep 30, 2025 | 55.65 Mn |
| Jun 30, 2025 | 53.08 Mn |
| Mar 31, 2025 | 53.08 Mn |
| Dec 31, 2024 | 53.08 Mn |
| Sep 30, 2024 | 53.08 Mn |
| Jun 30, 2024 | 53.08 Mn |
| Mar 31, 2024 | 53.08 Mn |
| Dec 31, 2023 | 48.46 Mn |
| Sep 30, 2023 | 48.46 Mn |
| Jun 30, 2023 | 48.46 Mn |
| Mar 31, 2023 | 48.46 Mn |
| Dec 31, 2022 | 34.35 Mn |
| Sep 30, 2022 | 52.94 Mn |
| Jun 30, 2022 | 52.94 Mn |
| Mar 31, 2022 | 52.94 Mn |
| Dec 31, 2021 | 52.94 Mn |
| Sep 30, 2021 | 52.93 Mn |